TLR agonists as adjuvants for cancer vaccines

Ji Kun Li, Jesse J. Balic, Liang Yu, Brendan Jenkins

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Otherpeer-review

16 Citations (Scopus)

Abstract

Toll-like receptors (TLRs) are one of the best characterised families of pattern recognition receptors (PRRs) and play a critical role in the host defence to infection. Accumulating evidence indicates that TLRs also participate in maintaining tissue homeostasis by controlling inflammation and tissue repair, as well as promoting antitumour effects via activation and modulation of adaptive immune responses. TLR agonists have successfully been exploited to ameliorate the efficacy of various cancer therapies. In this chapter, we will discuss the rationales of using TLR agonists as adjuvants to cancer treatments and summarise the recent findings of preclinical and clinical studies of TLR agonist-based cancer therapies.

Original languageEnglish
Title of host publicationAdvances in Experimental Medicine and Biology
EditorsIrun R. Cohen, Abel Lajtha, John D. Lambris, Rodolfo Paoletti
Place of PublicationGateway East Singapore
PublisherSpringer
Pages195-212
Number of pages18
Volume1024
ISBN (Electronic)978-981-10-5987-2
ISBN (Print) 978-981-10-5986-5
DOIs
Publication statusPublished - 2017

Publication series

NameAdvances in Experimental Medicine and Biology
Volume1024
ISSN (Print)0065-2598
ISSN (Electronic)2214-8019

Keywords

  • Adjuvant
  • Agonist
  • Clinical trial
  • Toll-like receptor

Cite this